Fibrocell Science, Inc. Announces Proposed Public Offering of Common Stock
9/26/2013 10:40:36 AM
EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company focused on the development of innovative products for aesthetic, medical and scientific applications, today announced its intention to offer and sell, shares of its common stock in an underwritten public offering pursuant to its existing shelf registration statement. The company also intends to grant to the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the public offering to cover over-allotments, if any. The company intends to use the net proceeds from the offering to fund Phase III clinical trials for additional azficel-T indications, to progress its collaboration programs with Intrexon Corporation and for working capital and general corporate and administrative expenses.
Help employers find you! Check out all the jobs and post your resume.
comments powered by